A Russian and Pakistani CRO Announce Network Alliance for Expansion of Global Clinical Trials Services
June 30, 2008
A Russian and Pakistani CRO Announce Network Alliance for Expansion of Global Clinical Trials Services
On June 30, 2008 Synergy Research Group (SynRG), a Russia-based CRO with more than 6-years experience in clinical trials in Russia announced the establishment of a new international CRO alliance with Metrics Research, a Pakistan-based CRO. This is the next step made by SynRG toward the formation of a CRO Worldwide Network capable to compete with global CROs in bids for large international multi-center clinical studies. The alliance currently includes CROs from the US, Europe, India, Pakistan and Ukraine.
“Pakistan with its 173 million strong population base, and a vast number of treatment-naïve patients, exactly like Russia, is one of the world’s emerging clinical trials market today. We are quite certain that both companies will benefit from allowing their clients the international capabilities. Together we are able to offer our sponsors access to more than 300 million patients,” said Elena Zhuk, General Director and CEO at SynRG.
“The Central and South Asian nexus is pivotal in providing clinical research services to the growing, evolving and competitive R&D industry of the world. Pakistan is already on the radar screen of multinational Pharma and CRO’s. Several Phase II, III FDA registration studies are currently ongoing in Pakistan. This ‘natural’ alliance between Metrics Research of Pakistan and SynRG of Russia will reap the benefits of this untapped market – Especially at a time when the government of Pakistan and relevant ministries are promoting clinical research activities in Pakistan”, stated Metrics Research’s Chief Executive, Khurram Zaki Khan.
Metrics Research is the first registered Contract Clinical Research and Site Management Organization (CRO/SMO) of Pakistan providing a comprehensive range of services in, project management, clinical operations and monitoring, data management, biostatistics, medical report writing, regulatory affairs, quality assurance, professional clinical research personnel training and development programs, country specific medical consultancy.
Igor Stefanov, SynRG’s Director for Business Development commented, “Now we're able to conduct trials in Pakistan also via our new partner. We are also planning some joint marketing and business development tasks – By preparing and sending proposals, and conduct presentations to the existing clients and prospects, and assist each other with related language and cultural translation issues.”
“Metrics Research’s mission is to forge collaborations and partnerships, to share knowledge and information, identify and/ or leverage common corporate strengths for business propagation and mutual profitability”, stated Faisal Roohi, Project and Business Development Manager for Metrics Research.
About SynRG
Synergy Research Group (SynRG™) is a Russian contract research organization, which has been successfully operating throughout Russia and the CIS member-states since 2002. SynRG™ offers a broad range of services for conducting clinical trials for Russian and foreign pharmaceutical and biotechnological companies – from regulatory affairs to pharmaco-economic surveys. The company has its own clinical depot in Moscow, with the total area of 1950 square feet. Today, Synergy Research Group is represented in Moscow, Saint-Petersburg, Novosibirsk, Yekaterinburg, Perm and Almaty. The company’s headquarters are in Moscow.For more information, please visit www.synrg-pharm.com
About Metrics Research
Metrics Research is the first registered Contract Clinical Research and Site Management Organization (CRO/SMO) of Pakistan. Set up by the People Group of Companies, located in Karachi, it caters to the clinical development programs of the pharmaceutical, biotechnology and medical device industries at a global level.
For more information, please visit www.mrcro.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.